| Identification | Back Directory | [Name]
Acetamide, N-[4-[[[3-(phenylamino)-2-quinoxalinyl]amino]sulfonyl]phenyl]- | [CAS]
301357-76-6 | [Synonyms]
Acetamide, N-[4-[[[3-(phenylamino)-2-quinoxalinyl]amino]sulfonyl]phenyl]- | [Molecular Formula]
C22H19N5O3S | [MOL File]
301357-76-6.mol | [Molecular Weight]
433.48 |
| Hazard Information | Back Directory | [Uses]
BMD4503-1 is a quinoxaline derivative. BMD4503-1 can inhibit the LRP5/6-Sclerostin interaction and regulate the Wnt signaling pathway[1]. | [References]
[1] Choi J, et al. In silico discovery of quinoxaline derivatives as novel LRP5/6-sclerostin interaction inhibitors. Bioorg Med Chem Lett. 2018 Apr 1;28(6):1116-1121. DOI:10.1016/j.bmcl.2018.01.050 |
|
|